Enliven CFO sells 6,018 shares after option exercise

Enliven Therapeutics’ CFO exercised options and sold 6,018 ELVN shares under a pre-arranged Rule 10b5-1 trading plan.

Rhea-AI Filing Summary

Enliven Therapeutics, Inc. (ELVN) reported that its chief financial officer, Benjamin Hohl, exercised stock options for 3,982 shares of Common Stock at an exercise price of $14.85 per share on September 17, 2026. The same day, he sold a total of 6,018 shares of Common Stock in multiple trades at weighted-average prices between about $50.03 and $51.49. Following the option exercise, he held 181,018 stock options from the original grant, and certain equity holdings are in the form of restricted stock units. All reported trades were effected under a Rule 10b5-1 trading plan adopted on March 18, 2026.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 5 txns

Insider Hohl Benjamin

Role CHIEF FINANCIAL OFFICER

Sold 6,018 shs ($303K)

Approx. gross sale proceeds $303K

Approx. exercise cost $59K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) F1, F6	3,982	$0.00	$0.00
Exercise	Common Stock F1, F2	3,982	$14.85	$59K
Sale	Common Stock F1, F3, F2	3,535	$50.0286	$177K
Sale	Common Stock F1, F4, F2	2,194	$50.7158	$111K
Sale	Common Stock F1, F5, F2	289	$51.4929	$15K

Holdings After Transaction: Stock Option (right to buy) — 181,018 contracts (Direct); Common Stock — 38,000 shares (Direct)

Footnotes (6)

1. F1. The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026.
2. F2. Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
3. F3. This transaction was executed in multiple trades at prices ranging from $49.31 to $50.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
4. F4. This transaction was executed in multiple trades at prices ranging from $50.31 to $51.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
5. F5. This transaction was executed in multiple trades at prices ranging from $51.365 to $51.70. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
6. F6. The option, originally for 185,000 shares, vested as to one-fourth of the shares on February 13, 2025, and the remainder of the shares vest in 36 equal monthly installments thereafter.

Key Figures

Options exercised: 3,982 shares Exercise price: $14.85 per share Shares sold: 6,018 shares +5 more

8 metrics

Options exercised 3,982 shares Stock option exercise into Common Stock on September 17, 2026

Exercise price $14.85 per share Conversion price for stock options exercised on September 17, 2026

Shares sold 6,018 shares Total Common Stock sold on September 17, 2026

Sale price tranche 1 $50.03 per share Weighted-average price for 3,535 shares sold, trades from $49.31 to $50.30

Sale price tranche 2 $50.72 per share Weighted-average price for 2,194 shares sold, trades from $50.31 to $51.26

Sale price tranche 3 $51.49 per share Weighted-average price for 289 shares sold, trades from $51.365 to $51.70

Options remaining from grant 181,018 options Stock options held after exercising 3,982 options from original 185,000-share grant

Option expiration February 13, 2034 Expiration date of the stock option from which 3,982 shares were exercised

Key Terms

Rule 10b5-1 trading plan, restricted stock units (RSUs), weighted average sale price, contingent right

4 terms

Rule 10b5-1 trading plan regulatory

"The option exercise and sales ... were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units (RSUs) financial

"Certain of these securities are restricted stock units (RSUs). Each RSU represents"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Enliven Therapeutics (ELVN) disclose about CFO Benjamin Hohl’s recent trades?

Enliven Therapeutics disclosed that CFO Benjamin Hohl exercised stock options for 3,982 shares and sold 6,018 shares of Common Stock on September 17, 2026, all under a Rule 10b5-1 trading plan.

How many Enliven Therapeutics (ELVN) shares did the CFO sell and at what prices?

The CFO sold a total of 6,018 shares of Enliven Therapeutics Common Stock on September 17, 2026, in multiple trades at weighted-average prices of about $50.03, $50.72, and $51.49 per share, each within specified intraday price ranges.

What stock options did the Enliven Therapeutics (ELVN) CFO exercise in this Form 4?

He exercised 3,982 stock options at an exercise price of $14.85 per share, converting them into Common Stock. The option was originally for 185,000 shares and vests over time, with 181,018 options remaining after this exercise.

Were the Enliven Therapeutics (ELVN) CFO’s transactions under a Rule 10b5-1 plan?

Yes. The Form 4 states that the option exercise and sales were effected under a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2026, indicating they followed a pre-established trading schedule.

What vesting terms apply to the Enliven Therapeutics (ELVN) option exercised by the CFO?

The option, originally for 185,000 shares, vested as to one-fourth of the shares on February 13, 2025, with the remaining shares vesting in 36 equal monthly installments thereafter, according to the Form 4 footnote.

What are the restricted stock units (RSUs) mentioned in the Enliven Therapeutics (ELVN) filing?

The filing notes that certain reported securities are restricted stock units (RSUs), where each RSU represents a contingent right to receive one share of Enliven’s Common Stock, subject to the applicable vesting schedule and conditions of each RSU award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/21/2026 - 05:24 PM Accepted by SEC EDGAR 09/21/2026 - 05:23 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hohl Benjamin

(Last) (First) (Middle)

C/O ENLIVEN THERAPEUTICS, INC.

205 PARK ROAD

(Street)

BURLINGAME CALIFORNIA 94010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/17/2026		M(1)		3,982	A	$14.85	44,018(2)	D
Common Stock	09/17/2026		S(1)		3,535	D	$50.0286(3)	40,483(2)	D
Common Stock	09/17/2026		S(1)		2,194	D	$50.7158(4)	38,289(2)	D
Common Stock	09/17/2026		S(1)		289	D	$51.4929(5)	38,000(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$14.85	09/17/2026		M(1)			3,982	(6)	02/13/2034	Common Stock	3,982	$0	181,018	D

Explanation of Responses:

1. The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026.

2. Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

3. This transaction was executed in multiple trades at prices ranging from $49.31 to $50.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

4. This transaction was executed in multiple trades at prices ranging from $50.31 to $51.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

5. This transaction was executed in multiple trades at prices ranging from $51.365 to $51.70. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

6. The option, originally for 185,000 shares, vested as to one-fourth of the shares on February 13, 2025, and the remainder of the shares vest in 36 equal monthly installments thereafter.

	/s/ Benjamin Hohl	09/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)